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A B S T R A C T
Background: It has been clinically demonstrated that intradermal (ID) vaccines have a potential to confer a
superior immunogenic proﬁle compared to intramuscular (IM) or subcutaneous (SC) vaccines. In terms of
distribution of a vaccine antigen depending on the administration routes, at least two independent
immunogenic pathways of the vaccines have been proposed: (1) the antigen recognition by the immune
cells present at the vaccine-administered site and (2) the antigen recognition by the lymph node (LN)-
resident immune cells through the lymphatic ﬂow from the vaccine-administered site after the antigen is
directly delivered into the draining LNs.
Objective: In order to clarify the key components for the immunogenic pathway of the ID vaccine, the
correlation between the kinetics of the antigen distribution to the draining LNs and antibody responses to
the antigen were evaluated.
Methods: We compared the antibody responses in the groups with by surgical removal of the
administration site immediately after the ID administration, and by surgical removal of the draining LNs
before the ID administration.
Results: The results suggested that the efﬁcient and direct antigen delivery to the draining LNs plays an
important role in the antibody responses to the ID vaccine. Indeed, it was conﬁrmed that the direct
administration into the draining LNs with the antigen elicited comparable levels of the antibody
responses with the ID vaccine. At the cellular level, it was shown that the LN-resident immune cells such
as B cells, dendritic cells, and macrophages including medullary macrophages and subcapsular sinus
macrophages interacting with the antigens following the ID administration. Finally, we demonstrated by
immunoﬂuorescence analysis that the lymphatic vessels are more diffusely distributed in the dermis as
compared with the subcutaneous area and muscle.
Conclusion: The results of the present study suggested that the skin is an optimal tissue to facilitate the
vaccine antigen access to the draining LNs, which is an important immunogenic pathway of the ID
vaccine. Further elucidation of regulatory mechanisms underlying such an immunogenic pathway of the
ID vaccine would provide us with elements for the development of novel adjuvants and devices to
enhance the immunogenicity of the ID vaccines.
ã 2015 The Authors. Published by Elsevier Ireland Ltd on behalf of Japanese Society for Investigative
Dermatology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Most of the injection-type vaccines currently used in clinics are
administered via the intramuscular (IM) or subcutaneous (SC)
route, whereas the results of recent clinical studies have suggested
that a variety of intradermal (ID) vaccines, whose formulation
contains antigens of an inactivated-type, live-attenuated-type, or
recombinant proteins, have a potential to confer a superior
immunogenic proﬁle compared to an IM or SC vaccine [1–4]. Inociety for Investigative Dermatology. This is an open access article under the CC BY-
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tration of a reduced dosage of the rabies vaccine originally used for
the IM injection with an expectation to improve vaccination
coverage for post-exposure prophylaxis in low-income countries
[5]. The only ID vaccine currently marketed was ﬁrst launched in
2007 as a vaccination for seasonal inﬂuenza, and has been used in
the markets of several developed countries [6].
Because the dermis in humans is a thin tissue located at a depth
of less than 1 mm from the skin surface and the thickness of the
dermis is approximately 1–3 mm depending on the local site of the
body, both training and experience are generally required for
practitioners to perform an accurate and consistent ID injection by
using a standard needle and syringe, i.e., Mantoux technique. In
order to offer an easy and reliable ID vaccination, several different
types of ID administration devices have been developed, and their
excellent performance has been demonstrated in clinical studies
[7–9]. In fact, the results of the clinical studies have demonstrated
that the immunogenic proﬁle of the ID vaccine using such an ID
administration system is better than that of the SC vaccine, while
the safety proﬁle of the ID vaccine is similar to that of the SC
vaccine [7].
Recent scientiﬁc evidence has suggested that the skin has
functionally developed for recognition of invading foreign anti-
gens, while the immunogenic pathways of the ID vaccines remain
to be elucidated. Anatomically, the skin consists of two distinct
regions, i.e., the epidermis and dermis. The epidermis is derived
from ectoderm and is an epithelial layer that is primarily composed
of keratinocytes. Langerhans cells, known to have an antigen-
presenting function, are present primarily in the epidermis under
the steady-state condition. In contrast, the dermis is derived from
mesoderm and is a relatively cell-sparse tissue, forming a stromal
layer underneath the epidermis. It is populated primarily by
ﬁbroblasts that secrete components of the complex extracellular
matrix. In the steady-state condition, a variety of immune cells,
such as mast cells and dendritic cells (DCs), are present in the
dermis and play a pivotal role in the skin immune responses to
antigens [10]. The skin-resident DCs are believed to be responsible
for the ﬁrst-line surveillance of foreign antigens. After capture of
the antigens in the skin, they become differentiated and migrate
into the draining lymph node (LN), where they present antigenic
epitopes to cells, accounting for the acquired immune responses
[11–13].
In addition to such immunological properties, the skin has also
unique micro-vascular structures. The rich vascularization of the
dermis is assured by terminal arterioles forming the plexus of 65–
75 capillary loops/mm2 [14]. The extensive dermal lymphatic
network originates in the dermis close to the epidermis (papillary
dermis) as small lymphatic vessels (LVs), merging and forming
major channels in the deep layers of the dermis (reticular dermis),
which drain to the regional draining LNs. Such a vascular system
facilitates antigen migration via LVs and subsequent stimulation of
LN-resident immune cells [15].
The LNs are the secondary lymphoid tissue to facilitate the
cross-talk of innate and acquired immune responses. Two different
pathways have been proposed for the antigen presentation in LNs.
In addition to the pathway, and depending on migratory antigen-
presenting DCs as described above, the LNs have an independent
pathway to quarantine foreign antigens ﬂowing through afferent
LVs by LN-resident DCs and macrophages. After trapping antigens
in the LNs, such cells are also capable of activating antigen-speciﬁc
T cells, and induction of memory B cells, independent of antigen-
presenting DCs migrating from outside of LNs [16,17].
In the present study, the components of the skin immune
system and the skin lymphatic system required for the immuno-
genic pathway of the ID vaccine were examined by using mouse
models. The results suggested that efﬁcient antigen delivery todraining LNs and uptake of the antigen by LN-resident DCs and
macrophages, rather than skin-resident immune cells migrating
into the draining LNs from the skin, are a key to the immunoge-
nicity of the ID vaccine.
2. Materials and methods
2.1. Animals
BALB/c mice 6–10 weeks old were purchased from CLEA Japan or
CharlesRiver Japan. Micewere maintained undera speciﬁc pathogen
free condition. All immunization and treatments were performed
under ketamine-xylazine anesthesia. All experiments were per-
formed according to the guidelines of the Institutional Animal Care
and Use Committee of National Institutes of Biomedical Innovation,
Daiichi Sankyo and Kitasato Daiichi Sankyo vaccine.
2.2. Distribution of Evans Blue dye (EBD) and the antigen into draining
LN and LVs after ID administration
EBD (Sigma) was dissolved at 0.5% (weight/volume) in PBS. EBD
solution was injected into the ear pinna by using a 35 G needle
(React System). Within 5 s or 30 min after injection, the color
changes in the ear and LNs were recorded using a digital camera
(RICOH, CX6). Next, 20 mL of 0.15 mg/mL Alexa 647-labeled OVA
(Life technologies) in PBS was administered into the right ear pinna
or administered SC at right ear base near the auricular LNs. Thirty
minutes after injection, mice were euthanized, their LNs of interest
were collected and washed softly with PBS, and then their
ﬂuorescent intensities were examined by using an IVIS system
(Summit Pharmaceuticals international Corporation). The results
were shown as total ﬂuorescent intensity in the region of interest
(ROI). The equal-sized circular ROI was applied to the image of each
LN using Living Image1 software. In the same experiment, mice
were injected into ear pinna with 0.2 mg of Alexa 488-labeled OVA
in 2 mL of PBS. Immediately after injection, the injected ear was
removed and then the distribution of the ﬂuorescent signal was
examined under TCS SP5 confocal system (Leica, Wetzlar,
Germany) and processed with Leica LAS software.
2.3. Vaccination and measurement of antibody response
Inﬂuenza A H1N1 (A/Puerto Rico/8/34) hemagglutinin (HA)
protein (Sino biological) was used as the vaccine antigen and
prepared in different concentrations after either concentrated by
using Vivaspin 500, 10 kDa (GE healthcare) or dissolved in PBS.
Three micrograms of HA antigen was administered into the ear
pinna or administered SC at the ear base near the auricular LNs or
administered ID or SC at the back. Three weeks after vaccination,
antibody response speciﬁc to the HA antigen was measured by
ELISA. Ninety-six well plates were coated with 0.5 mg/mL of HA
antigen or with different concentrations (3-fold serial dilutions
from 0.25 mg/mL) of puriﬁed mouse IgG (Southern Biotech). Plates
were washed three times with PBS with 0.05% Tween 20 (Wash
buffer), and then treated with PBS with 0.05% Tween 20 containing
1% BSA (Blocking buffer). The sera from immunized mice were
diluted with blocking buffer. The diluted sera were added to plates
and then the plates were incubated for an hour at 25 C. After
washing, the plates were incubated with either horseradish
peroxidase-conjugated goat anti-mouse IgG, IgG1, or IgG2a
(Southern Biotech) for an hour. After washing, TMB microwell
peroxidase substrate (KPL) was added to the plates. Five to ten
minutes after incubation at 25 C, 2N sulfuric acid (Wako) was
added and ﬁnally absorbance at 450–540 nm was measured by
plate reader (Power wave HT, BioTek). The antibody concentration
in each serum sample was analyzed using Gen 51 software.
Fig. 1. Immunogenicity and antigen distribution into draining LNs following the ID vaccination.
(A) Mice (5 mice per group) were vaccinated with 3 mg of Flu HA antigen in 20 mL PBS. All mice were vaccinated into ear or back on their right sides. Blood samples were
collected at 21 days after immunization, and sera were prepared for ELISA. *, p values <0.05 by unpaired Student’s t-test. (B) Auricular LN is indicated by a black circle at 30 min
after being injected with 20 mL of EBD into the ear pinna. Scale bar indicates 3 mm. (C) Twenty microliters of Alexa 647-labeled OVA was administered ID or SC, and then the
indicated LNs were collected for IVIS imaging analysis. The results are shown as total ﬂuorescent intensity in ROI. Scale bar indicates 3 mm. (D) Mice (5 mice per group) were
vaccinated with 3 mg of Flu HA antigen in 20 mL PBS. Blood samples were collected at 21 days after vaccination and sera were prepared for ELISA. NC, naive mice as negative
control; SC, subcutaneous vaccination at the right ear base near the auricular LN; SC w/o right LN, right auricular LN was removed before SC immunization at the right ear base
near the auricular LN; ID, intradermal vaccination into the ear pinna; ID w/o right (left) LN, right (left) auricular LN was removed before ID immunization into right ear pinna.
****, p values <0.0001 by one-way ANOVA followed by Turkey’s test.
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Three micrograms of Alexa 488-labeled OVA in 20 mL of PBS
was injected ID or SC into the right ear or right back. Within 5 s,
30 min, or 24 h after injection, auricular LNs, right superﬁcial
cervical LNs, and right axillary LNs were isolated. LNs were
smashed in 10 mL of RPMI1640 supplemented with 1% FBS, 100 U/
mL penicillin, 100 mg/mL streptomycin, 500 U/mL Collagenase
type II (Worthington Biochemical), and 0.1 mg/mL DNase I
(Sigma) and incubated for 30 min at 37 C with mild rotation.
After washing with PBS, cells were suspended in FACS buffer (PBS
containing 1 mg/mL BSA and 1 mM EDTA) and incubated for
10 min on ice with 5 mg/mL anti-mouse CD16/32 mAb (BioL-
egend) to block Fcg receptors. Cells were then stained with each
antibody (PerCP/Cy5.5 anti-mouse/human CD11b, PE/Cy7 anti-
mouse/human CD45R/B220, APC/Cy7 anti-mouse CD3, PerCP/
Cy5.5 anti-mouse CD169, PE/Cy7 anti-mouse F4/80, APC anti-
mouse CD11c [Biolegend]) for 45–60 min on ice and analyzed on a
FACSVerse ﬂow cytometer (BD Biosciences). White blood cells
were gated based on forward scatter/side scatter. In order to
evaluate antigen uptake, geometric means of Alexa 488 were
computed to derive the mean ﬂuorescence intensity (MFI) of the
staining, and each MFI value was normalized using the MFI of the
same cell type in the same LN from naïve mice i.e., auto-
ﬂuorescence. The percentage of each cell population in white
blood cells was also calculated.
2.5. Immunoﬂuorescence analysis
The ear, thigh, and back were removed and embedded in super
cryo embedding medium (SCEM, section lab). After freezing,
samples were cut into 7 mm-thick sections. The sections were
dried on the slide glass, and ﬁxed with 1% of paraformaldehyde in
PBS (Wako) for 20 min at 25 C. The sections were washed three
times with PBS, and blocked with PBS containing 1% BSA. After
being incubated with 1 mg/mL rabbit anti-mouse LYVE-1 anti-
bodies (Acris antibodies) for at least 12 h and less than 18 h at 4 C,
the sections were washed three times and then further incubated
with Alexa 546-conjugated goat anti-rabbit IgG (Thermo ﬁsher
scientiﬁc) diluted at 1:1000 for an hour at 25 C. The sections were
washed and then mounted with mounting medium (Sigma). The
sections were examined by ﬂuorescence microscopy (Biorevo,
KEYENCE).
3. Results
3.1. Immunogenicity of the intradermal ID vaccine is higher than that
of the subcutaneous SC vaccine
In order to compare the immunogenicity of the ID vaccine and
that of the SC vaccine, antibody responses were evaluated in
mouse models of the inﬂuenza HA vaccine. Twenty-one days after
administration with a single dose of the HA vaccine, the levels of
serum anti-HA total IgG were signiﬁcantly higher in the ID
vaccine group than in the SC vaccine group, which was shown
when examined independently at different local sites, i.e., the ear
and back (Fig. 1A). In general, the higher levels of antigen-speciﬁc
IgG2a represent Th1 immune responses such as cellular immune
responses, while those of antigen-speciﬁc IgG1 represent
Th2 immune responses such as humoral immune responses
[18]. The ratio of serum anti-HA IgG2a to anti-HA IgG1 was higher
in the ID vaccine group than in the SC vaccine group
(Supplemental data, Table 1), suggesting that the ID vaccine
induces more Th1-deviated antibody responses than the SC
vaccine.3.2. The ID vaccination confers a prompt and efﬁcient delivery of the
antigen into the draining LNs
We employed the ear pinna as one of the ID administration sites
because it is experimentally easy to access the auricular LNs, which
are the draining LNs of the ear pinna; it is also advantageous for
consistent ID injection with less possibility of misinjection into a
SC area since the ear pinna of mice has marginal amounts of SC
tissues. In order to conﬁrm the draining LNs of the ear pinna, Evans
Blue Dye (EBD) was injected into the ear pinna, and then the
following color changes of subcutaneous LVs and LNs in the
cervical and axillary regions were examined. As shown in Fig. 1B,
color changes were apparently detected in one of the auricular LNs
within a few seconds after the injection (Fig. 1B). In contrast, no
color changes were detected in the other subcutaneous tissues,
including the regional superﬁcial cervical LNs and axillary LNs
(data not shown). It was further examined whether the model
antigen ﬂows into the draining auricular LN after being adminis-
tered into the ear pinna. Thirty minutes after administration with
Alexa 647-labeled OVA into the ear pinna, signiﬁcant intensities of
Alexa 647 ﬂuorescence were detected by IVIS imaging system only
in one of the auricular LNs, but not in the other regional LNs, such
as the superﬁcial cervical LNs and axillary LNs (Fig. 1C). In contrast,
after the administration with Alexa 647-labeled OVA into the ear
base near the auricular LN, as a control SC administration, no
signiﬁcant intensities of ﬂuorescence were detected in any
regional LNs located at the cervical and axillary regions
(Fig. 1C). Taken together, the results suggested that a prompt
and efﬁcient delivery of the antigen into the draining LNs is a
unique event following the ID vaccination, which is not apparent
following the SC vaccination.
3.3. The draining LNs are a key component in the immunogenic
pathway of the ID vaccine
To examine whether the draining LNs play a role in the
immunogenic pathway of the ID vaccine, the levels of serum anti-
HA total IgG were compared in each vaccine group with and
without the surgical removal of the auricular LNs before
administration. As shown in Fig. 1D, the levels of serum anti-HA
total IgG in the ID vaccine group were dramatically decreased
when the right side (administration side) of the auricular LN was
removed before the administration. In contrast, the levels of total
IgG were comparable in the ID vaccine group with the surgical
removal of the left side (non-administration side) of the auricular
LNs and in the ID vaccine group without the surgical removal. The
levels of total IgG were also comparable in the SC vaccine group
with and without the surgical removal of right side (administration
side) of the auricular LNs. Taken together, the results suggested
that the draining LNs play a signiﬁcant role in the immunogenic
pathway of the ID vaccine.
3.4. Variety of immune cells interact with the antigen in the draining
LNs following the ID vaccination
In order to identify the cell populations interacting with the
antigen in the draining LNs after the ID vaccination, the numbers of
different cell types interacting with Alexa 488-labeled OVA were
examined by ﬂow cytometry. Each cell type was characterized as
follows: T cell, CD3+ B220; B cell, B220+ CD3; dendritic cell (DC),
CD11c+; DC and macrophage, CD11b+; subcapsular sinus macro-
phage (SSM), CD169+ F4/80; medullary macrophage (MM),
CD169+ F4/80+. In the draining auricular LNs on the administration
side (right side) at 30 min after the ID administration, the
intensities of Alexa 488 ﬂuorescence were detected in B cells,
DCs, macrophages including SSMs and MMs, but hardly detected in
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and macrophages and MMs showed a signiﬁcantly higher intensity
of ﬂuorescence after the ID administration as compared with those
after the SC administration. In contrast, the ﬂuorescent intensities
in the CD11b+ fraction of DCs and macrophages and MMs at 24 h
after the administration were comparable between those in the ID
administration group and in the SC administration group.
Collectively, the results suggested that the kinetics of the antigen
distribution to the draining LNs and its interaction with immune
cells is different between the ID vaccine and the SC vaccine. In
being consistent with the data obtained by using EBD or by using
Alexa 647-labelled OVA detected by IVIS imaging system, no
signiﬁcant intensities of Alexa 488 ﬂuorescence were detected in
any cell populations in the superﬁcial cervical LNs on the injectionA 
Fig. 2. A variety of immune cells interact with the antigen in the draining LNs followi
After being administered into the ear pinna or administered SC at the ear base near th
indicated LNs were collected. Single cell suspension was prepared and then subjected 
(A) MFIs in the fraction of CD3+ B220, B220+ CD3, CD11c+, CD11b+, CD169+ F4/80, or CD
with SC vaccine groups (open circle) at within 5 s (immediately), 30 min and 24 h after adm
percentage of each cell population in the right auricular LNs after being administered into
axillary LNs after being administered ID or SC into the right back within 5 s (Immediatel
Dunnett’s test. N = 3–4 per group.side (right side) or in the auricular LNs on the non-administration
side (left side). We also evaluated the ﬂuorescent signal in the
draining axillary LNs after ID or SC administration with Alexa 488-
labeled OVA in the right back. Similar to the ear pinna model as
described above, DCs and macrophages including MMs in the
draining axillary LNs showed signiﬁcantly higher ﬂuorescent
intensities at 30 min after the ID administration as compared with
the SC administration (Fig. 2A). We also examined the ratio of each
cell population in the right auricular LNs after administration into
the ear pinna or SC administration at the ear base near the
auricular LNs and in the right axillary LNs after ID or SC
administration into the right back at times of within 5 s, 30 min,
or 24 h after administration (Fig. 2B). No signiﬁcant differences in
the ratio of each cell population were detected followingB
ng the ID vaccination.
e auricular LNs or administered ID or SC in the back with Alexa 488-labeled OVA,
to ﬂow cytometry analysis.
169+ F4/80+ from the indicated LNs. ID vaccine groups (ﬁlled circle) were compared
inistration. *, p values <0.05; **, p values <0.01 by unpaired Student’s t-test. (B) The
 the ear pinna or administered SC at the ear base near the auricular LNs or in the right
y), 30 min, or 24 h after administration. No signiﬁcant differences were detected by
M. Tozuka et al. / Journal of Dermatological Science 82 (2016) 38–45 43vaccination, suggesting that the cell migration from outside of LNs
was scarcely induced at least 24 h after the ID vaccine administra-
tion.
3.5. Portion of the antigen delivered into the draining LNs is a key for
the antibody responses induced by the ID vaccine
In order to spatially evaluate whether a portion of the HA
vaccine that was delivered into the draining LNs, or remained at the
administration sites is involved in the immunogenic pathway of
the ID vaccine, the levels of serum anti-HA total IgG were
compared among the ID vaccine groups with and without the
surgical removal of the ear pinna after the vaccination, and in the
group in which the mice were vaccinated via intra-LNs (iLNs) after
the auricular LNs were exposed by the surgical operation. The
levels of anti-HA total IgG in the ID vaccine group with the removal
of the ear within 5 s (Immediately) after the vaccination was
slightly lower than those in the ID vaccine group without the
removal operation (Fig. 3, p = 0.44). Of interest, the ID vaccine
groups with the removal of the ear pinna at 30 min or 24 h after the
vaccination showed comparable levels of anti-HA total IgG to the
ID vaccine group without the removal operation (Fig. 3). In
addition, the levels of anti-HA total IgG in the group in which the
mice were vaccinated via iLN were comparable with those in the ID
vaccine group without any operation and were higher than those in
the SC vaccine group. Overall, the results suggested that a portion
of the antigen immediately delivered into the draining LNs is
enough for the antibody induction by the ID vaccine.
3.6. The kinetics of the antigen distribution into the draining LNs
depend on the volume of the vaccine formulation
Since it has been elucidated that the dermal lymphatic network
originated from the dermis converges into the LVs, culminating inA
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Fig. 3. Importance of the antigen distribution into draining LNs for immunogenicity
of the ID vaccine.
Mice (10 mice per group) were immunized with 3 mg of Flu HA antigen in 20 mL PBS.
All mice were immunized on their right side in the ear pinna (ID) or administered SC
at the right ear base near the auricular LNs (SC). Blood samples were collected
21 days after immunization, and sera were prepared for ELISA. In some ID groups,
the ear pinna was removed within 5 s (Immediately), 30 min, or 24 h after ID
vaccination (Removal). In other groups, no surgical operations were performed. In
the group of iLN, 3 mg of Flu HA antigen was directly injected into the right auricular
LN. NC: naive mice as negative control. *, p values <0.05 by one-way ANOVA
followed by Turkey’s test.linking to the draining LNs, the kinetics of the antigen molecules
from the ID administration site to the regional draining LNs as well
as the dynamics of the immunogenicity were examined. It was
hypothesized that the liquid volume of the vaccine formula might
have an inﬂuence on the immunogenicity of the ID vaccination due
to the void volume from the vaccination site of the skin to the
activation site in the LNs (Supplemental data, Fig. 1). In order to
examine the void volume in the ear pinna model, immediately
after administered with either of three different vaccine formula,
in which each contained the same 3 mg of HA but either 2, 20, or
40 mL in total volume, mice were treated with or without the
surgical removal of the ear pinna. As shown in Fig. 4, the levels of
anti-HA total IgG were comparable among the ID vaccine groups
without the removal of the ear pinna (No-removal) (Fig. 4, No
removal, ID 2 mL vs ID 20 mL vs ID 40 mL). In contrast, in the ID
vaccine groups with the removal of the ear pinna (Removal), the
levels of anti-HA total IgG of the 2 mL formulation (ID 2 mL) were
lower than those of the 20 mL formulation (ID 20 mL). The levels of
anti-HA total IgG were comparable among the ID vaccine groups of
the 20 mL or 40 mL formulation (ID 20 mL or ID 40 mL) and No-
removal or Removal. These results taken together suggested that
the void volume in this ear pinna model is between 2 and 20 mL,
and the volume of 20–40 mL is enough to immediately deliver the
antigen to the draining LNs required for the antibody responses,
suggesting that the kinetics of the antigen into the draining LNs
depend on the volume of the vaccine formulation.
3.7. Distribution of LVs in the administration sites for the ID and SC
vaccines
In order to examine the distribution of LVs, the immunoﬂuo-
rescence analysis was performed using tissue sections of the thigh,
back, and ear including the skin, SC area, and muscle. As shown in
Fig. 5A, the result of immunoﬂuorescence staining of the surface of
LV endothelial cells by using anti-LYVE-1 antibody showed that LVs
are diffusely present in the dermis and fascia, but hardly present in
the SC area and muscle as consistent with previous reports [19,20].
The LV-like structure was also detected after Alexa 488-labeled
OVA and EBD solution was injected into the ear pinna by ID
administration (Fig. 5B). Both of the Alexa 488-labeled OVA and
EBD solution were observed in the microvascular structure, whichA
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Fig. 4. Inﬂuence of the volume of vaccine formula on the antigen distribution and
immunogenicity of the ID vaccine.
Mice (10 mice per group) were administered with either of three different vaccine
formulas in which each contained the same 3 mg of HA, but either 2, 20, or 40 mL in
total volume. Immediately after administration, mice were treated with or without
the surgical removal of the right ear pinna, ‘Removal’ or ‘No removal’, respectively.
Blood samples were collected 21 days after administration, and sera were subjected
to ELISA. NC: naive mice as negative control. **, p values <0.01 by one-way ANOVA
followed by Turkey’s test.
Fig. 5. Immunoﬂuorescence analysis of the distribution of LVs and the antigen after the ID administration.
(A) Bright ﬁeld and ﬂuorescent microscopic images were obtained from the sections of the thigh, back, and ear in naïve mice. The images were shown below at 10 fold
magniﬁcations; scale bar indicates 400 mm. Epi, epidermis; Derm, dermis; SC, subcutaneous; M, muscle. (B) Upper panel: immediately after 0.2 mg in 2 mL of Alexa 488-
labeled OVA was administered into the ear pinna, the image under transmitted light, that of green ﬂuorescence by confocal microscopy, and that of the merge were shown.
Scale bar indicates 1 mm. Lower panel: photograph of the mice ear pinna immediately after injection with 2 or 10 mL of 0.5% EBD solution. scale bar indicates 3 mm.
44 M. Tozuka et al. / Journal of Dermatological Science 82 (2016) 38–45was likely to be LVs but not blood vessels, suggesting that the
antigen is efﬁciently transferred into LVs after ID administration.
4. Discussion
The key ﬁndings of the present study are: (1) the efﬁcient and
direct antigen delivery to the draining LNs plays an important role
in the antibody responses to the ID vaccine, (2) the LN-resident
immune cells, such as B cells, DCs, SSMs, and MMs, interact with
the antigens following the ID administration, and (3) the LVs are
more diffusely distributed in the dermis as compared with the
subcutaneous area and muscle.
In this study, by using the ID vaccination model of the ear pinna
administered with HA vaccines, it was demonstrated that the bolus
ID administration of 20 mL of vaccine formulation promptly
delivered the antigen to the draining auricular LNs, which is
enough to induce antibody responses even after removal of the
vaccinated side of the ear pinna immediately after the vaccination.
In contrast, although the levels of antibody responses induced by
the ID administration with the 2 mL vaccine formulation were
comparable with those of the 20 mL vaccine formulation, such
antibody responses by the 2 mL vaccine formulation were shut off
when the vaccinated side of the ear pinna had been removed
immediately after the administration. Overall, the results sug-
gested that although most portions of the 2 mL vaccine formulationreside inside the vaccinated ear pinna immediately after the
vaccination, the antigen is thereafter delivered to the draining LNs
by the intrinsic lymphatic ﬂow, leading to the induction of
antibody responses. We also observed that after the bolus ID
injection, an excess volume of EBD passes through the primal
draining LNs, and ﬂows into the consecutive draining LNs without
any leakage from LVs, suggesting that the ID vaccine can confer the
direct and sequential delivery of the antigen into the local
networks of secondary lymphoid tissues.
The vaccination methods for delivering the antigen into the skin
are classiﬁed into three types: (1) a liquid vaccine formulation
administered into the skin, (2) a solid vaccine formulation on or in
a microneedle patch attached on the skin surface, and (3) a topical
vaccine formulation applied on the skin surface. From the view
point of the kinetics of the antigen distribution the results of this
study and others suggested that most portion of the antigen in the
former liquid vaccine formulation is directly delivered into LVs and
draining LNs where it is trapped in the draining LN-resident
immune cells and that in contrast to the bolus administration
method, most of the portion of the antigen in the latter solid and
topical formula is mainly trapped by skin-resident immune cells,
which then migrate into the draining LNs [21,22]. Such different
patterns of the antigen distribution and antigen recognition by the
immune system may result in the different nature of immunoge-
nicity toward the antigen. The results also suggested that the
M. Tozuka et al. / Journal of Dermatological Science 82 (2016) 38–45 45patterns of the antigen distribution are different following the
administration with the ID and SC vaccine, and that the ID vaccine
confers the delivery of the antigen more efﬁciently into the
draining LNs, which results in its immunogenic proﬁle superior to
the SC vaccine’s. As the results shown in Fig. 3, the ID vaccine
groups with the removal of the ear pinna at 30 min after the
vaccination showed comparable levels of anti-HA total IgG to the
ID vaccine group without the removal operation. These results
strongly suggest that, even though the levels of the interaction
between the vaccine antigen and the LN-resident cells after the ID
administration ﬁnally declines to those 24 h after the SC
administration, such an interaction within 30 min after the ID
administration is crucial for the robust immune responses. The
pronounced antigen interaction with LN-resident B cells, DCs, and
macrophages is suggested to be associated with the superior
immunogenic proﬁle of the ID vaccine, since the results of recent
clinical trials of our novel ID inﬂuenza vaccine clearly indicated
that the ID vaccine has the potential to induce faster and higher
serum antibody responses to the antigen as compared with the
conventional SC vaccine currently used in Japan [7,8].
It is likely that the efﬁciency of the antigen delivery to the
draining LNs following the ID vaccination varies depending on the
nature and conditions of the local lymphatic system of the
administration sites, such as the efﬁciency of the antigen’s access
to the draining LNs and the transportation efﬁciency of the antigen
by the intrinsic lymphatic ﬂow. It may be of clinical value to ﬁnd
the best ID vaccination sites and conditions in which the highest
immunogenicity can be achieved in addition to being capable of
providing a safe, accurate, and consistent injection. Although the
results of this study suggested no marked change of innate
immune responses, i.e., the levels of pro-inﬂammatory cytokine
production (data not shown), at the ID administration sites, it may
be also of great value to elucidate mechanisms underlying the
regulation of the antigen transportation from the skin to the
draining LNs. The results of our preliminary experiments so far do
not suggest that pre-treatment with substances known to induce
vasodilation and enhancing extravasation, such as histamines,
modulates the efﬁciency of the antigen delivery from the skin to
the draining LNs. Drugs or apparatus enhancing such an antigen
transportation may be applied to an adjuvant for the ID vaccine.
In summary, the results of the present study suggested that
efﬁcient antigen delivery to draining LNs and subsequent uptake of
the antigen by the immune cells pre-existing in draining LNs,
rather than those migrating into the draining LNs from the skin, are
a key for the immunogenicity of the ID vaccine. Further studies are
required to elucidate whether such different cell populations, each
having a different immunological function, associate or do not
associate with each other to induce antigen-speciﬁc immune
responses. Hopefully, further elucidation of immunological mech-
anisms in LNs underlying the interaction between innate and
acquired immune responses might shed light on a variety of
elements that can promote strategies to develop more effective
and safe ID vaccines in the future.
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